{
    "Trade/Device Name(s)": [
        "WaveSense Jazz Blood Glucose Monitoring System"
    ],
    "Submitter Information": "AgaMatrix",
    "510(k) Number": "K241304",
    "Predicate Device Reference 510(k) Number(s)": [
        "K072413"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "June 6, 2024",
    "Summary Letter Received Date": "May 9, 2024",
    "Submission Date": "May 9, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "WaveSense Jazz Blood Glucose Monitoring System"
    ],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for WaveSense Jazz Blood Glucose Monitoring System for quantitative measurement of glucose in capillary whole blood from finger stick, palm, and forearm",
    "Indications for Use Summary": "Intended for quantitative measurement of glucose in fresh capillary whole blood from finger stick, palm, and/or forearm for at-home (OTC) use by persons with diabetes to monitor diabetes control effectiveness",
    "fda_folder": "Clinical Chemistry"
}